Xpert MTB/RIF 检出耐利福平结核后未常规开展二线药敏试验的影响:多中心观察性研究
该多中心观察性研究纳入南非 1332 例经 Xpert MTB/RIF 检出的耐利福平结核患者,分析二线药敏试验的完成情况及时间。仅 44.7% 患者获得氟喹诺酮类和二线注射剂药敏结果,中位等待 53 天;在 252 例有完整二线药敏结果的患者中,40.1% 可能起始了次优方案。
要点
- 仅 44.7% 的耐利福平结核患者获得氟喹诺酮类和二线注射剂药敏结果。
- 二线药敏结果中位等待时间为 53 天(范围 8–259 天)。
- 有完整二线药敏结果者中 40.1% 可能起始了次优方案。
核心结论
- 许多经 Xpert 诊断的耐利福平结核患者起始了次优方案,调整治疗所需信息在中位 7 周后才对半数患者可得。
研究设计与样本
- 多中心观察性研究,纳入南非西开普省 2011 年 11 月至 2013 年 6 月及东开普省、自由邦省和豪登省 2012 年 11 月至 2013 年 12 月经 Xpert 检出的耐利福平结核患者,共 1332 例。
主要发现
- 1332 例耐利福平结核患者中仅 44.7%(596 例)获得氟喹诺酮类和二线注射剂药敏结果,西开普省为 55.8%(466/835),其他省份为 26.2%(130/497)。
- 涂片阴性患者和年龄 ≤10 岁患者获得二线药敏结果的可能性更低(RR=0.72,95%CI 0.64–0.81;RR=0.49,95%CI 0.26–0.79)。
- 二线药敏结果中位时间为 53 天(范围 8–259 天)。
- 252 例有完整二线药敏结果的患者中,101 例(40.1%)可能起始了次优方案,西开普省为 46.8%,其他省份为 25.3%。
临床怎么用
- Xpert 检出耐利福平结核后应尽快完成二线药敏试验以指导方案调整。
- 对涂片阴性和年龄 ≤10 岁患者需关注二线药敏试验的可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND.: Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results. We quantified the second-line DST results time and proportion of patients potentially placed on suboptimal therapy. METHODS.: We included RR-tuberculosis patients detected using Xpert at the South African National Health Laboratory Services (NHLS) of the Western Cape between November 2011 and June 2013 and at Eastern Cape, Free State, and Gauteng NHLS between November 2012 and December 2013. We calculated time from specimen collection to phenotypic second-line DST results. We identified isoniazid and ethionamide resistance mutations on line probe assay and performed pyrazinamide sequencing. RESULTS.: Among 1332 RR-tuberculosis patients, only 44.7% (596) had second-line DST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Western Cape and 26.2% (130 of 497) in the other provinces. Patients with smear negative disease and age ≤10 years were less likely to have a result (risk ratio [RR] = 0.72; 95% CI, 0.64-0.81 and RR = 0.49; 95% CI, 0.26-0.79). Median time to second-line DST was 53 days (range, 8-259). Of the 252 patients with complete second-line DST, 101 (40.1%) potentially initiated a suboptimal regimen: 46.8% in the Western Cape and 25.3% in the other provinces. CONCLUSIONS.: Many South Africans diagnosed with RR-tuberculosis by Xpert initiate a suboptimal regimen, with information to adjust therapy available in half of all patients after a median 7 weeks. Algorithm completion and time delays remain challenging.
引用
- Jacobson KR, Barnard M, Kleinman MB, et al. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017. PMID: 28199520. doi:10.1093/cid/cix128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。